Supply of baricitinib for Czech hospital pharmacy.
The Czech Republic, through the Central Pharmacy of the University Hospital in Hradec Králové, is procuring a long-term contract for the supply of baricitinib, an immunosuppressive agent used in the treatment of rheumatoid arthritis and other conditions. The contract covers the period from 2026 onwards, with an estimated annual volume of approximately 1,200 packages. The tender requires bidders to provide proof of registration of the medicinal product in the Czech Republic and compliance with Good Distribution Practice. The contract value is not explicitly stated but based on the volume and typical pricing, it is likely in the range of 100,000 to 1,000,000 EUR.